APO Research
Talk to an analyst

APO RESEARCH · REPORT

Management of Antithrombin

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Management of Antithrombin Market Analysis and Forecast 2026-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchManagement of Antithrombin Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Management of Antithrombin Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Management of Antithrombin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Management of Antithrombin Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Management of Antithrombin Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Management of Antithrombin market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Management of Antithrombin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Management of Antithrombin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Management of Antithrombin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Management of Antithrombin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Management of Antithrombin include Takeda, Grifols, Scripps Laboratories Inc., rEVO Biologics Inc., Lee Biosolutions, Kedrion S.p.A. and CSL Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Management of Antithrombin, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Management of Antithrombin, also provides the revenue of main regions and countries. Of the upcoming market potential for Management of Antithrombin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Management of Antithrombin revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Management of Antithrombin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Management of Antithrombin revenue, projected growth trends, production technology, application and end-user industry.

Management of Antithrombin Segment by Company

Takeda

Grifols

Scripps Laboratories Inc.

rEVO Biologics Inc.

Lee Biosolutions

Kedrion S.p.A.

CSL Limited

Management of Antithrombin Segment by Type

Liquid

Lyophilized

Management of Antithrombin Segment by Application

Diagnostics

Therapeutics

Research

Management of Antithrombin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Management of Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Management of Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Management of Antithrombin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Management of Antithrombin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Management of Antithrombin company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Management of Antithrombin revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Management of Antithrombin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Liquid Major Player Table 3. Lyophilized Major Player Table 4. Global Management of Antithrombin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Diagnostics Major Player Table 6. Therapeutics Major Player Table 7. Research Major Player Table 8. Management of Antithrombin Industry Trends Table 9. Management of Antithrombin Industry Drivers Table 10. Management of Antithrombin Industry Opportunities and Challenges Table 11. Management of Antithrombin Industry Restraints Table 12. Global Management of Antithrombin Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Management of Antithrombin Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Management of Antithrombin Market Share by Region (2021-2026) Table 15. Global Management of Antithrombin Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Management of Antithrombin Market Share by Region (2027-2032) Table 17. Global Management of Antithrombin Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Management of Antithrombin Revenue Market Share by Players (2021-2026) Table 19. Global Management of Antithrombin Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Management of Antithrombin Key Players Headquarters & Area Served Table 21. Global Management of Antithrombin Players, Product Type & Application Table 22. Global Management of Antithrombin Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Management of Antithrombin by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Management of Antithrombin Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Management of Antithrombin Revenue Market Share by Type (2021-2026) Table 29. Global Management of Antithrombin Revenue Market Share by Type (2027-2032) Table 30. Global Management of Antithrombin Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Management of Antithrombin Revenue Market Share by Application (2021-2026) Table 34. Global Management of Antithrombin Revenue Market Share by Application (2027-2032) Table 35. Takeda Company Information Table 36. Takeda Business Overview Table 37. Takeda Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Management of Antithrombin Product Portfolio Table 39. Takeda Recent Development Table 40. Grifols Company Information Table 41. Grifols Business Overview Table 42. Grifols Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Grifols Management of Antithrombin Product Portfolio Table 44. Grifols Recent Development Table 45. Scripps Laboratories Inc. Company Information Table 46. Scripps Laboratories Inc. Business Overview Table 47. Scripps Laboratories Inc. Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Scripps Laboratories Inc. Management of Antithrombin Product Portfolio Table 49. Scripps Laboratories Inc. Recent Development Table 50. rEVO Biologics Inc. Company Information Table 51. rEVO Biologics Inc. Business Overview Table 52. rEVO Biologics Inc. Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. rEVO Biologics Inc. Management of Antithrombin Product Portfolio Table 54. rEVO Biologics Inc. Recent Development Table 55. Lee Biosolutions Company Information Table 56. Lee Biosolutions Business Overview Table 57. Lee Biosolutions Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Lee Biosolutions Management of Antithrombin Product Portfolio Table 59. Lee Biosolutions Recent Development Table 60. Kedrion S.p.A. Company Information Table 61. Kedrion S.p.A. Business Overview Table 62. Kedrion S.p.A. Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Kedrion S.p.A. Management of Antithrombin Product Portfolio Table 64. Kedrion S.p.A. Recent Development Table 65. CSL Limited Company Information Table 66. CSL Limited Business Overview Table 67. CSL Limited Management of Antithrombin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. CSL Limited Management of Antithrombin Product Portfolio Table 69. CSL Limited Recent Development Table 70. North America Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 71. North America Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 72. North America Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 73. North America Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 74. North America Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Management of Antithrombin Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Management of Antithrombin Revenue by Country (US$ Million) & (2027-2032) Table 77. Europe Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 78. Europe Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 79. Europe Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 80. Europe Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 81. Europe Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Europe Management of Antithrombin Revenue by Country (2021-2026) & (US$ Million) Table 83. Europe Management of Antithrombin Revenue by Country (US$ Million) & (2027-2032) Table 84. China Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 85. China Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 86. China Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 87. China Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 88. Asia Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 89. Asia Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 90. Asia Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 91. Asia Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 92. Asia Management of Antithrombin Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Asia Management of Antithrombin Revenue by Region (US$ Million) & (2021-2026) Table 94. Asia Management of Antithrombin Revenue by Region (US$ Million) & (2027-2032) Table 95. SAMEA Management of Antithrombin Revenue by Type (2021-2026) & (US$ Million) Table 96. SAMEA Management of Antithrombin Revenue by Type (2027-2032) & (US$ Million) Table 97. SAMEA Management of Antithrombin Revenue by Application (2021-2026) & (US$ Million) Table 98. SAMEA Management of Antithrombin Revenue by Application (2027-2032) & (US$ Million) Table 99. SAMEA Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. SAMEA Management of Antithrombin Revenue by Country (2021-2026) & (US$ Million) Table 101. SAMEA Management of Antithrombin Revenue by Country (US$ Million) & (2027-2032) Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Management of Antithrombin Image Figure 2. Global Management of Antithrombin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Management of Antithrombin Market Size Share 2021 VS 2025 VS 2032 Figure 4. Liquid Image Figure 5. Lyophilized Image Figure 6. Global Management of Antithrombin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Management of Antithrombin Market Size Share 2021 VS 2025 VS 2032 Figure 8. Diagnostics Image Figure 9. Therapeutics Image Figure 10. Research Image Figure 11. Global Management of Antithrombin Market Size (US$ Million) & (2021-2032) Figure 12. Global Management of Antithrombin Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Management of Antithrombin Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Management of Antithrombin Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Management of Antithrombin Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Management of Antithrombin Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Management of Antithrombin Revenue Market Share by Type (2021-2032) Figure 19. Global Management of Antithrombin Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Management of Antithrombin Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Management of Antithrombin Revenue Market Share by Application (2021-2032) Figure 22. North America Management of Antithrombin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Management of Antithrombin Revenue Share by Type (2021-2032) Figure 24. North America Management of Antithrombin Revenue Share by Application (2021-2032) Figure 25. North America Management of Antithrombin Revenue Share by Country (2021-2032) Figure 26. United States Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Management of Antithrombin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Management of Antithrombin Revenue Share by Type (2021-2032) Figure 31. Europe Management of Antithrombin Revenue Share by Application (2021-2032) Figure 32. Europe Management of Antithrombin Revenue Share by Country (2021-2032) Figure 33. Germany Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Management of Antithrombin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Management of Antithrombin Revenue Share by Type (2021-2032) Figure 43. China Management of Antithrombin Revenue Share by Application (2021-2032) Figure 44. Asia Management of Antithrombin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Management of Antithrombin Revenue Share by Type (2021-2032) Figure 46. Asia Management of Antithrombin Revenue Share by Application (2021-2032) Figure 47. Asia Management of Antithrombin Revenue Share by Region (2021-2032) Figure 48. Japan Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Management of Antithrombin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Management of Antithrombin Revenue Share by Type (2021-2032) Figure 56. SAMEA Management of Antithrombin Revenue Share by Application (2021-2032) Figure 57. SAMEA Management of Antithrombin Revenue Share by Country (2021-2032) Figure 58. Brazil Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Management of Antithrombin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Lyophilized
Applications
  • Diagnostics
  • Therapeutics
  • Research
Companies covered
  • Takeda
  • Grifols
  • Scripps Laboratories Inc.
  • rEVO Biologics Inc.
  • Lee Biosolutions
  • Kedrion S.p.A.
  • CSL Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Management of Antithrombin Market by Type
  3. 1.2.1 Global Management of Antithrombin Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Liquid
  5. 1.2.3 Lyophilized
  6. 1.3 Management of Antithrombin Market by Application
  7. 1.3.1 Global Management of Antithrombin Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Diagnostics
  9. 1.3.3 Therapeutics
  10. 1.3.4 Research
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Management of Antithrombin Market Dynamics
  1. 2.1 Management of Antithrombin Industry Trends
  2. 2.2 Management of Antithrombin Industry Drivers
  3. 2.3 Management of Antithrombin Industry Opportunities and Challenges
  4. 2.4 Management of Antithrombin Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Management of Antithrombin Market Perspective (2021-2032)
  2. 3.2 Global Management of Antithrombin Growth Trends by Region
  3. 3.2.1 Global Management of Antithrombin Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Management of Antithrombin Market Size by Region (2021-2026)
  5. 3.2.3 Global Management of Antithrombin Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Management of Antithrombin Revenue by Players
  2. 4.1.1 Global Management of Antithrombin Revenue by Players (2021-2026)
  3. 4.1.2 Global Management of Antithrombin Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Management of Antithrombin Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Management of Antithrombin Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Management of Antithrombin Key Players Headquarters & Area Served
  7. 4.4 Global Management of Antithrombin Players, Product Type & Application
  8. 4.5 Global Management of Antithrombin Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Management of Antithrombin Market CR5 and HHI
  11. 4.6.3 2025 Management of Antithrombin Tier 1, Tier 2, and Tier 3
5 Management of Antithrombin Market Size by Type
  1. 5.1 Global Management of Antithrombin Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Management of Antithrombin Revenue by Type (2021-2032)
  3. 5.3 Global Management of Antithrombin Revenue Market Share by Type (2021-2032)
6 Management of Antithrombin Market Size by Application
  1. 6.1 Global Management of Antithrombin Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Management of Antithrombin Revenue by Application (2021-2032)
  3. 6.3 Global Management of Antithrombin Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Management of Antithrombin Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Management of Antithrombin Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Grifols
  8. 7.2.1 Grifols Company Information
  9. 7.2.2 Grifols Business Overview
  10. 7.2.3 Grifols Management of Antithrombin Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Grifols Management of Antithrombin Product Portfolio
  12. 7.2.5 Grifols Recent Developments
  13. 7.3 Scripps Laboratories Inc.
  14. 7.3.1 Scripps Laboratories Inc. Company Information
  15. 7.3.2 Scripps Laboratories Inc. Business Overview
  16. 7.3.3 Scripps Laboratories Inc. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Scripps Laboratories Inc. Management of Antithrombin Product Portfolio
  18. 7.3.5 Scripps Laboratories Inc. Recent Developments
  19. 7.4 rEVO Biologics Inc.
  20. 7.4.1 rEVO Biologics Inc. Company Information
  21. 7.4.2 rEVO Biologics Inc. Business Overview
  22. 7.4.3 rEVO Biologics Inc. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  23. 7.4.4 rEVO Biologics Inc. Management of Antithrombin Product Portfolio
  24. 7.4.5 rEVO Biologics Inc. Recent Developments
  25. 7.5 Lee Biosolutions
  26. 7.5.1 Lee Biosolutions Company Information
  27. 7.5.2 Lee Biosolutions Business Overview
  28. 7.5.3 Lee Biosolutions Management of Antithrombin Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Lee Biosolutions Management of Antithrombin Product Portfolio
  30. 7.5.5 Lee Biosolutions Recent Developments
  31. 7.6 Kedrion S.p.A.
  32. 7.6.1 Kedrion S.p.A. Company Information
  33. 7.6.2 Kedrion S.p.A. Business Overview
  34. 7.6.3 Kedrion S.p.A. Management of Antithrombin Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Kedrion S.p.A. Management of Antithrombin Product Portfolio
  36. 7.6.5 Kedrion S.p.A. Recent Developments
  37. 7.7 CSL Limited
  38. 7.7.1 CSL Limited Company Information
  39. 7.7.2 CSL Limited Business Overview
  40. 7.7.3 CSL Limited Management of Antithrombin Revenue and Gross Margin (2021-2026)
  41. 7.7.4 CSL Limited Management of Antithrombin Product Portfolio
  42. 7.7.5 CSL Limited Recent Developments
8 North America
  1. 8.1 North America Management of Antithrombin Revenue (2021-2032)
  2. 8.2 North America Management of Antithrombin Revenue by Type (2021-2032)
  3. 8.2.1 North America Management of Antithrombin Revenue by Type (2021-2026)
  4. 8.2.2 North America Management of Antithrombin Revenue by Type (2027-2032)
  5. 8.3 North America Management of Antithrombin Revenue Share by Type (2021-2032)
  6. 8.4 North America Management of Antithrombin Revenue by Application (2021-2032)
  7. 8.4.1 North America Management of Antithrombin Revenue by Application (2021-2026)
  8. 8.4.2 North America Management of Antithrombin Revenue by Application (2027-2032)
  9. 8.5 North America Management of Antithrombin Revenue Share by Application (2021-2032)
  10. 8.6 North America Management of Antithrombin Revenue by Country
  11. 8.6.1 North America Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Management of Antithrombin Revenue by Country (2021-2026)
  13. 8.6.3 North America Management of Antithrombin Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Management of Antithrombin Revenue (2021-2032)
  2. 9.2 Europe Management of Antithrombin Revenue by Type (2021-2032)
  3. 9.2.1 Europe Management of Antithrombin Revenue by Type (2021-2026)
  4. 9.2.2 Europe Management of Antithrombin Revenue by Type (2027-2032)
  5. 9.3 Europe Management of Antithrombin Revenue Share by Type (2021-2032)
  6. 9.4 Europe Management of Antithrombin Revenue by Application (2021-2032)
  7. 9.4.1 Europe Management of Antithrombin Revenue by Application (2021-2026)
  8. 9.4.2 Europe Management of Antithrombin Revenue by Application (2027-2032)
  9. 9.5 Europe Management of Antithrombin Revenue Share by Application (2021-2032)
  10. 9.6 Europe Management of Antithrombin Revenue by Country
  11. 9.6.1 Europe Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Management of Antithrombin Revenue by Country (2021-2026)
  13. 9.6.3 Europe Management of Antithrombin Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Management of Antithrombin Revenue (2021-2032)
  2. 10.2 China Management of Antithrombin Revenue by Type (2021-2032)
  3. 10.2.1 China Management of Antithrombin Revenue by Type (2021-2026)
  4. 10.2.2 China Management of Antithrombin Revenue by Type (2027-2032)
  5. 10.3 China Management of Antithrombin Revenue Share by Type (2021-2032)
  6. 10.4 China Management of Antithrombin Revenue by Application (2021-2032)
  7. 10.4.1 China Management of Antithrombin Revenue by Application (2021-2026)
  8. 10.4.2 China Management of Antithrombin Revenue by Application (2027-2032)
  9. 10.5 China Management of Antithrombin Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Management of Antithrombin Revenue (2021-2032)
  2. 11.2 Asia Management of Antithrombin Revenue by Type (2021-2032)
  3. 11.2.1 Asia Management of Antithrombin Revenue by Type (2021-2026)
  4. 11.2.2 Asia Management of Antithrombin Revenue by Type (2027-2032)
  5. 11.3 Asia Management of Antithrombin Revenue Share by Type (2021-2032)
  6. 11.4 Asia Management of Antithrombin Revenue by Application (2021-2032)
  7. 11.4.1 Asia Management of Antithrombin Revenue by Application (2021-2026)
  8. 11.4.2 Asia Management of Antithrombin Revenue by Application (2027-2032)
  9. 11.5 Asia Management of Antithrombin Revenue Share by Application (2021-2032)
  10. 11.6 Asia Management of Antithrombin Revenue by Country
  11. 11.6.1 Asia Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Management of Antithrombin Revenue by Country (2021-2026)
  13. 11.6.3 Asia Management of Antithrombin Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Management of Antithrombin Revenue (2021-2032)
  2. 12.2 SAMEA Management of Antithrombin Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Management of Antithrombin Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Management of Antithrombin Revenue by Type (2027-2032)
  5. 12.3 SAMEA Management of Antithrombin Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Management of Antithrombin Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Management of Antithrombin Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Management of Antithrombin Revenue by Application (2027-2032)
  9. 12.5 SAMEA Management of Antithrombin Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Management of Antithrombin Revenue by Country
  11. 12.6.1 SAMEA Management of Antithrombin Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Management of Antithrombin Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Management of Antithrombin Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst